Murine tumor xenografts show promising anti-growth responses to inhibition of glutamine (glutaminase) metabolism (63, 64), and clinical trials are currently ongoing to test the efficacy of inhibiting glutaminase using a small molecule inhibitor (CB-839, Calithera Biosciences) in multiple types and stages of cancer (NCT020718626; NCT020718887; NCT03163667).8 This evidence concerns the gene GLS and neoplasm.